Downregulation and altered function of natural killer cells in hepatitis B virus patients treated with entecavir

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 3, 2013, Pages 190-196

  Zhao, Ping Wei ^a   Jia, Fei Yong ^a   Shan, Yu Xing ^a   Ji, Hui Fan ^a   Feng, Jun Yan ^a   Niu, Jun Qi ^a   Ayana, Desalegn A ^b   Jiang, Yan Fang ^a  

^a JILIN UNIVERSITY   (China)

^b HARAMAYA UNIVERSITY   (Ethiopia)

Author keywords

Entecavir; Hepatitis B virus; Natural killer cell activating receptors; Natural killer cells

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD56 ANTIGEN; ENTECAVIR; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN EXPRESSION; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMETRY; DEGRANULATION; DOWN REGULATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; MALE; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PHENOTYPE; T LYMPHOCYTE SUBPOPULATION; VIRUS IMMUNITY; VIRUS LOAD;

ADULT; ANTIGENS, CD3; ANTIGENS, CD56; ANTIVIRAL AGENTS; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GUANINE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, NATURAL KILLER CELL; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84874295886     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12048     Document Type: Article

References (26)

1. Wang FS, Xing LH, Liu MX et al. Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection. World J. Gastroenterol. 2001; 7: 537-1.
2. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect. Dis. 2008; 8: 167-8.
3. Gish RG, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-4.
4. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1011-20.
5. Sheng YJ, Liu JY, Tong SW et al. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B. A systematic review and meta-analysis. Virol. J. 2011; 8: 393.
6. Fisicaro PC, Valdatta C, Boni M et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009; 58: 974-2.
7. Wieland SF, Chisari FV. Stealth and cunning. Hepatitis B and hepatitis C viruses. J. Virol. 2005; 79: 9369-80.
8. Orange JS, Ballas ZK. Natural killer cells in human health and disease. Clin. Immunol. 2006; 118: 1-10.
9. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat. Immunol. 2008; 9: 503-10.
10. Moretta L, Moretta A. Unravelling natural killer cell function: Triggering and inhibitory human NK receptors. EMBO J. 2004; 23: 255-9.
11. Moretta A. Natural killer cells and dendritic cells: Rendezvous in abused tissues. Nat. Rev. Immunol. 2002; 2: 957-4.
12. Zhang Z, Zhang S, Zou Z et al. Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 2011; 53: 73-5.
13. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology 2006; 43(Suppl.): S173-81.
14. Jiang Y, Ma Z, Xin G et al. Th1, Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm. 2010; 2010: 143026.
15. Rehermann B, Naoumov NV. Immunological techniques in viral hepatitis. J. Hepatol. 2007; 46: 508-20.
16. Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol. Int. 2008; 2: 163-8.
17. Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect. Drug Resist. 2011; 4: 55-4.
18. Zhang JY, Zhang Z, Lin F et al. Interleukin-17-producing CD4(+) T cells increase with severity of damage in patients with chronic hepatitis B. Hepatology 2010; 51: 81-91.
19. Zhang Z, Chen D, Yao J et al. Increased infiltration of intrahepatic DC subsets closely correlate with viral control and liver injury in immune active pediatric patients with chronic hepatitis B. Clin. Immunol. 2007; 122: 173-80.
20. Zhang Z, Zou ZS, Fu JF et al. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure. J. Hepatol. 2008; 49: 396-6.
21. Oliviero B, Varchetta S, Paudice E et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009; 137: 1160.
22. Varchetta S, Mele D, Mantovani S et al. Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. Hepatology 2012; 56: 841-9.
23. Chen Y, Wei H, Sun R, Dong Z, Zhang J, Tian Z. Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells. Hepatology 2007; 46: 706-5.
24. Zou Y, Chen T, Han M et al. Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. J. Immunol. 2010; 184: 466-5.
25. Ethuin F, Gérard B, Benna JE, et al. Human neutrophils produce interferon gamma upon stimulation by interleukin-12. Lab. Invest. 2004; 84: 1363-1.
26. Maul-Pavicic A, Chiang SC, Rensing-Ehl A et al. ORAI1-mediated calcium influx is required for human cytotoxic lymphocyte degranulation and target cell lysis. Proc. Natl Acad. Sci. USA 2011; 108: 3324-9.